Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 10:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 350 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hepatic Malignancies Clear all
Terminated Not applicable Interventional Results available

Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors

NCT00730483
View directory record Official record
Conditions
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Metastatic Cancer
Interventions
PVA microporous hydrospheres/doxorubicin hydrochloride
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 120 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2017 · Synced Sep 11, 2026, 10:03 AM EDT
Completed Phase 1 Interventional

A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas

NCT01625351
View directory record Official record
Conditions
Ewing Sarcoma, Gastrointestinal Tumor, Germ Cell Tumor, Hepatic Tumor, Lymphoma, Wilms Tumor, Rhabdoid Tumor, Clear Cell Carcinoma, Renal Cell Carcinoma, Melanoma, Neuroblastoma, Rhabdomyosarcoma, Non-rhabdomyosarcoma
Interventions
alemtuzumab, fludarabine, sirolimus, Busulfan, melphalan, stem cells, CliniMACS
Drug · Biological · Device
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Years to 21 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 11, 2026, 10:03 AM EDT
Recruiting No phase listed Observational

Evaluation of Portal Vein Stenting in Patients With Portal Vein Stenosis and Gastrointestinal Cancers

NCT04629677
View directory record Official record
Conditions
Malignant Digestive System Neoplasm
Interventions
Electronic Health Record Review, Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 11, 2026, 10:03 AM EDT
Not yet recruiting Phase 2 Interventional

HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization

NCT07612007
View directory record Official record
Conditions
Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Resectable Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Darizmetinib, Embolization Therapy, Hepatectomy, Magnetic Resonance Imaging, Placebo Administration, Positron Emission Tomography
Procedure · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 11, 2026, 10:03 AM EDT
Terminated Phase 2 Interventional Results available

Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant

NCT05027425
View directory record Official record
Conditions
Hepatocellular Carcinoma, Cirrhosis, Portal Hypertension
Interventions
Durvalumab, Tremelimumab, Liver Transplant
Drug · Procedure
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
St Louis, Missouri • Cincinnati, Ohio • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 11, 2026, 10:03 AM EDT
Completed Phase 1 Interventional

A Study in Cancer Patients With Hepatic Impairment to Evaluate the Pharmacokinetics and Safety of NKTR-102 (Etirinotecan Pegol)

NCT01991678
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors in Patients With Hepatic Impairment
Interventions
145 mg/m2 NKTR 102, 120 mg/m2 NKTR 102, 50 mg/m2 NKTR 102
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
3
States / cities
Los Angeles, California • San Francisco, California • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Sep 11, 2026, 10:03 AM EDT
Completed No phase listed Observational

Feasibility of a Minimally Invasive Image-Guided Surgery System for Hepatic Procedures

NCT01286428
View directory record Official record
Conditions
Liver Cancer
Interventions
Not listed
Lead sponsor
Pathfinder Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 13, 2012 · Synced Sep 11, 2026, 10:03 AM EDT
Completed Phase 1 Interventional

Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma

NCT01938729
View directory record Official record
Conditions
Intrahepatic Cholangiocarcinoma, Peripheral Cholangiocarcinoma, Cholangiolar Carcinoma, Cholangiocellular Carcinoma) (ICC)
Interventions
Liver resection and placement of hepatic artery infusion pump, FLOXURIDINE, DEXAMETHASONE, GEMCITABINE
Procedure · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2020 · Synced Sep 11, 2026, 10:03 AM EDT
Recruiting Phase 2 Interventional

Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy

NCT07201519
View directory record Official record
Conditions
Colorectal Cancer Metastatic, Intrahepatic Cholangiocarcinoma
Interventions
Hepatic Artery Infusion Pump (HAIP), Standard Treatment, Community Treatment, Systemic Chemotherapy Standard of Care, Standard Of Care targeting driver mutations
Device · Procedure · Drug
Lead sponsor
Michael J Cavnar, MD
Other
Eligibility
18 Years to 99 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 11, 2026, 10:03 AM EDT
Active, not recruiting Not applicable Interventional

Evaluation of a Simple-Prep Controlled Embolic

NCT06453642
View directory record Official record
Conditions
Embolization, Vascular Tumor, Renal Angiomyolipoma, Renal Cell Carcinoma, Bone Tumor, Portal Vein Embolization
Interventions
GPX® Embolic Device
Device
Lead sponsor
Fluidx Medical Technology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
15
States / cities
La Jolla, California • Aurora, Colorado • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 11, 2026, 10:03 AM EDT
Terminated Phase 1 Interventional

Dose Escalation Study Combining Oral Capecitabine (Xeloda) and Radiotherapy for Patients With Unresectable Liver or Cholangiocarcinoma

NCT00216437
View directory record Official record
Conditions
Cancer of Liver
Interventions
Capecitabine (Xeloda)
Drug
Lead sponsor
James A. Haley Veterans Administration Hospital
Federal
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 11, 2007 · Synced Sep 11, 2026, 10:03 AM EDT
Not listed No phase listed Observational

Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers

NCT04682847
View directory record Official record
Conditions
Liver Neoplasms, Hepatic Cirrhosis, Hepatic Carcinoma, Liver Cancer, Liver Metastases, Liver Carcinoma, Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatic Atrophy
Interventions
Ferumoxytol injection
Drug
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
18 Years to 89 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Sep 11, 2026, 10:03 AM EDT
Withdrawn Phase 1 Interventional

ABT-888, Carboplatin, and Paclitaxel for Cancer With Liver or Kidney Problems

NCT01419548
View directory record Official record
Conditions
Neoplasms
Interventions
ABT-888, Carboplatin, Paclitaxel
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 110 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
2
States / cities
Bethesda, Maryland • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 11, 2026, 10:03 AM EDT
Completed Phase 2 Interventional Results available

Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors

NCT01177007
View directory record Official record
Conditions
Liver Neoplasms
Interventions
TheraSphere, Yttrium-90 glass Microspheres
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 27, 2017 · Synced Sep 11, 2026, 10:03 AM EDT
Completed Phase 3 Interventional

Controlled Trial Comparing Nomogram-based Versus Standard Allocation of Acute Normovolemic Hemodilution (ANH) During Hepatic Resection

NCT00902343
View directory record Official record
Conditions
Liver Cancer
Interventions
nomogram-based selection for acute normovolemic hemodilution, standard selection for ANH based on a planned resection of 3 or more segments
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 12, 2015 · Synced Sep 11, 2026, 10:03 AM EDT
Completed Phase 1 Interventional

A Phase I Study of Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the Liver

NCT00001576
View directory record Official record
Conditions
Colorectal Neoplasm, Liver Neoplasm, Neoplasm Metastasis
Interventions
Melphalan, Floxuridine, Leucovorin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 11, 2026, 10:03 AM EDT
Completed Phase 1 Interventional

A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Hepatic Impairment

NCT02301104
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
TAS-102
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
8
States / cities
Scottsdale, Arizona • Duarte, California • Santa Monica, California + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Sep 11, 2026, 10:03 AM EDT
Active, not recruiting Phase 4 Interventional

Hepatic Artery Chemotherapy for Patients With Localized Pancreas Cancer

NCT05634720
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
HA Chemotherapy
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 11, 2026, 10:03 AM EDT
Completed Phase 1 Interventional

Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment

NCT02161770
View directory record Official record
Conditions
Solid Tumours
Interventions
AZD9291 tablet dosing, Pharmacokinetic sampling - AZD9291, Pharmacokinetic sampling - AZ5140 and AZ7550
Drug · Procedure
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
5
States / cities
San Diego, California • Atlanta, Georgia • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2019 · Synced Sep 11, 2026, 10:03 AM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetic Study of Liposomal Vincristine in Patients With Malignant Melanoma & Hepatic Dysfunction

NCT00145041
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Vincristine Sulfate Liposomes Injection
Drug
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Sep 11, 2026, 10:03 AM EDT
Recruiting Phase 2 Interventional

PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma

NCT05286814
View directory record Official record
Conditions
Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc), Intrahepatic Bile Duct Cancer, Colorectal Neoplasms, Colorectal Cancer, Cholangiocarcinoma, Bile Duct Neoplasms, Bile Duct Cancer, Adrenocortical Carcinoma (ACC), Adrenal Cortical Carcinoma, Adrenal Gland Cancer, Adrenal Gland Neoplasms, Adrenal Cortex Neoplasms
Interventions
Dexamethasone, PDS01ADC, Intera 3000 Hepatic Artery Infusion Pump (HAIP), Floxuridine
Drug · Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 11, 2026, 10:03 AM EDT
Completed Phase 1 Interventional

Paclitaxel Administered by HAI to Patients With Advanced Cancer and Dominant Liver Involvement

NCT00508326
View directory record Official record
Conditions
Advanced Cancer
Interventions
Paclitaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
13 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2012 · Synced Sep 11, 2026, 10:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate ASP0367 in Participants With Mild/Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function

NCT04942964
View directory record Official record
Conditions
Hepatic Impairment, Healthy Volunteers
Interventions
Bocidelpar
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2024 · Synced Sep 11, 2026, 10:03 AM EDT
Withdrawn Phase 2 Interventional

Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer

NCT00386516
View directory record Official record
Conditions
Cancer of the Bile Duct, Gallbladder Cancer
Interventions
GM-CT-01, 5-Fluorouracil
Drug
Lead sponsor
Galectin Therapeutics Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Sep 11, 2026, 10:03 AM EDT